Renata PLC (DSE:RENATA)

Bangladesh flag Bangladesh · Delayed Price · Currency is BDT
416.50
+0.90 (0.22%)
At close: Apr 28, 2026
-15.45%
Market Cap 47.67B
Revenue (ttm) 44.26B
Net Income (ttm) 2.54B
Shares Out 114.70M
EPS (ttm) 22.11
PE Ratio 18.79
Forward PE 15.16
Dividend 5.50 (1.32%)
Ex-Dividend Date Nov 18, 2025
Volume 10,667
Average Volume 23,407
Open n/a
Previous Close 415.60
Day's Range 415.20 - 417.50
52-Week Range 372.00 - 548.00
Beta 0.02
RSI 43.65
Earnings Date Apr 29, 2026

About Renata

Renata PLC manufactures, markets, and distributes pharmaceuticals, animal health medicines, oncology-based, agro-based, poultry, and consumer products in Bangladesh. The company offers generic products, including amantadine, clindamycin, clindamycin, colchicine, dipyridamole, escitalopram, fludrocortisone acetate, hydrocortisone, prednisolone, propylthiouracil, sertraline hydrochloride, terbinafine, and topiramate tablet and capsules. It also offers specialty products, such as SHK-024, an antidepressant, and SHK 007, to reduce toxicity in pedia... [Read more]

Industry Pharmaceutical Preparations
Founded 1972
Employees 8,366
Stock Exchange Dhaka Stock Exchange
Ticker Symbol RENATA
Full Company Profile

Financial Performance

In fiscal year 2025, Renata's revenue was 42.89 billion, an increase of 13.74% compared to the previous year's 37.71 billion. Earnings were 2.22 billion, a decrease of -38.58%.

Financial Statements

News

There is no news available yet.